Long Term Safety Study of Tanezumab in Chronic Low Back Pain

Inclusion Criteria: * Written informed consent prior to completing any of the study procedures. * Female patients must meet one of the following criteria: 1\) Female patients of non childbearing potential - Must be post menopausal, defined as women who are \>=45 years old with amenorrhea for 24 consecutive months (regardless of FSH levels), or women who are amenorrheic for at least 1 year AND have a serum Follicle Stimulating Hormone (FSH) level greater than 30 IU/L at Screening for the parent double blind CLBP study; or Must be surgically sterile, defined as having had a hysterectomy and/or bilateral oophorectomy. 2.) Female patients of child bearing potential: must not be pregnant or lactating, and must be abstinent or use adequate contraception (2 forms of birth control, one of which must be a barrier method), and must have a negative serum pregnancy test at Screening (within 30 days prior to Baseline) and a negative urine pregnancy test at Baseline prior to initial dosing * Male patients must agree that they and their female spouses / partners will use adequate contraception (2 forms of birth control, one of which must be barrier method) or be of non childbearing potential. * Females of child bearing potential and males must be willing to use approved methods of contraception from commencement of screening procedures until 16 weeks after the last dose of IV study medication. * Patient must be able to comply with lifestyle guidelines, scheduled visits, treatment plan, laboratory tests, and other study procedures * Patient has been treated in a parent tanezumab double blind CLBP study * Patient has completed the Preferred Rollover Time Point visit of the double blind CLBP parent study or has been withdrawn for lack of efficacy. At least eight weeks but no more than 12 weeks have elapsed since the last study medication infusion in the parent study. Patients are permitted to enter the extension study up to 12 weeks after their last dose of study medication in their parent study (or 4 weeks after the End of Treatment visit) Exclusion Criteria: * Failed screening in a parent tanezumab double blind CLBP study * Withdrawn from a parent tanezumab double blind CLBP study for an adverse event * Pregnant women, lactating mothers, women suspected of being pregnant, and women who wish to become pregnant during the course of clinical study * Use of any investigational medication within 30 days prior to Baseline (3 months for any investigational biological other than …